[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100591135":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":25,"locations":31,"responsibleParty":42,"collaborators":24,"id":44,"slug":24,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":24,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":51,"minAge":52,"maxAge":24,"enrollmentInfo":53,"targetDuration":24,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":24,"overallStatus":62,"whyStopped":24,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},{"fullName":5,"class":6},"Addpharma Inc.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Sequence A","EXPERIMENTAL","Period 1: Fasted, Period 2: Fed",[13],"Drug: PA-111",{"label":15,"type":10,"description":16,"interventionNames":17},"Sequence B","Period 1: Fed, Period 2: Fasted",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","PA-111","PA-111 1Tab., Per Oral",[9,15],null,[26],{"name":27,"role":28,"phone":29,"phoneExt":24,"email":30},"JeongEun Park","CONTACT","+82-31-891-6989","parkje@addpharma.co.kr",[32],{"facility":33,"status":24,"city":34,"state":24,"zip":24,"country":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":24},"H Plus Yangji Hospital","Seoul","South Korea",{"type":37,"coordinates":38},"Point",[39,40],126.9784,37.566,{"lat":40,"lon":39},{"type":43,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100591135",false,"NCT06976489","The Food Effect on PK Characteristics and Safety Profiles of PA-111","An Open-label, Randomized, Single-dose, 2-sequence, 2-period, Crossover Study to Evaluate the Food Effect on the Safety and the Pharmacokinetics of PA-111 in Healthy Adult Volunteers","Inclusion Criteria:\n\n* Body weight equal to or greater than 50kg (Female 45kg) and Body mass index (BMI) between 18.0 kg\u002Fm2 and 30.0 kg\u002Fm2 at the time of screening visit\n* The Age equal to or greater than 19 in healthy volunteers at the time of screening visit\n\nExclusion Criteria:\n\n* Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration\n* Other exclusions applied",true,"ALL","19 Years",{"count":54,"type":55},40,"ESTIMATED","INTERVENTIONAL",[58],"PHASE1","Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of PA-111 in healthy subjects.",[61],"Mixed Dyslipidemia","NOT_YET_RECRUITING","2025-05-09",{"date":65,"type":66},"2025-05-16","ACTUAL",{"date":68,"type":55},"2025-05",{"date":70,"type":55},"2025-07",{"name":5,"class":6},1]